ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk

Stolarova, L; Kleiblova, P; Zemankova, P; Stastna, B; Janatova, M; Soukupova, J; Achatz, MI; Ambrosone, C; Apostolou, P; Arun, BK; Auer, P; Barnard, M; Bertelsen, B; Biobank Japan; Blok, MJ; Boddicker, N; Brunet, J; Burnside, ES; Calvello, M; Campbell, I; Chan, SH; Chen, F; Chiang, JB; Coppa, A; Cortesi, L; Crujeiras-Gonzalez, A; Consortium CZECANCA; De Leeneer, K; De Putter, R; DePersia, A; Devereux, L; Domchek, S; Efremidis, A; Engel, C; Ernst, C; Evans, DGR; Feliubadalo, L; Fostira, F; Fuentes-Rios, O; Gomez-Garcia, EB; Gonzalez, S; Haiman, C; van Overeem Hansen, T; Hauke, J; Hodge, J; Hu, C; Huang, H; Ishak, NDB; Iwasaki, Y; Konstantopoulou, I; Kraft, P; Lacey, J; Lazaro, C; Li, N; Lim, WK; Lindstrom, S; Lori, A; Martinez, E; Martins, A; Matsuda, K; Matullo, G; McInerny, S; Michailidou, K; Montagna, M; Monteiro, ANA; Mori, L; Nathanson, K; Neuhausen, SL; Nevanlinna, H; Olson, JE; Palmer, J; Pasini, B; Patel, A; Piane, M; Poppe, B; Radice, P; Renieri, A; Resta, N; Richardson, ME; Rosseel, T; Ruddy, KJ; Santamarina, M; Dos Santos, ES; Teras, L; Toland, AE; Trentham-Dietz, A; Vachon, CM; Volk, AE; Weber-Lassalle, N; Weitzel, JN; Wiesmuller, L; Winham, S; Yadav, S; Yannoukakos, D; Yao, S; Zampiga, V; Zethoven, M; Zhang, ZW; Zima, T; Spurdle, AB; Vega, A; Rossing, M; Del Valle, J; De Nicolo, A; Hahnen, E; Claes, KBM; Ngeow, J; Momozawa, Y; James, PA; Couch, FJ; Macurek, L; Kleibl, Z

Author(s): Stolarova, L; Kleiblova, P; Zemankova, P; Stastna, B; Janatova, M; Soukupova, J; Achatz, MI; Ambrosone, C; Apostolou, P; Arun, BK; Auer, P; Barnard, M; Bertelsen, B; Biobank Japan; Blok, MJ; Boddicker, N; Brunet, J; Burnside, ES; Calvello, M; Campbell, I; Chan, SH; Chen, F; Chiang, JB; Coppa, A; Cortesi, L; Crujeiras-Gonzalez, A; Consortium CZECANCA; De Leeneer, K; De Putter, R; DePersia, A; Devereux, L; Domchek, S; Efremidis, A; Engel, C; Ernst, C; Evans, DGR; Feliubadalo, L; Fostira, F; Fuentes-Rios, O; Gomez-Garcia, EB; Gonzalez, S; Haiman, C; van Overeem Hansen, T; Hauke, J; Hodge, J; Hu, C; Huang, H; Ishak, NDB; Iwasaki, Y; Konstantopoulou, I; Kraft, P; Lacey, J; Lazaro, C; Li, N; Lim, WK; Lindstrom, S; Lori, A; Martinez, E; Martins, A; Matsuda, K; Matullo, G; McInerny, S; Michailidou, K; Montagna, M; Monteiro, ANA; Mori, L; Nathanson, K; Neuhausen, SL; Nevanlinna, H; Olson, JE; Palmer, J; Pasini, B; Patel, A; Piane, M; Poppe, B; Radice, P; Renieri, A; Resta, N; Richardson, ME; Rosseel, T; Ruddy, KJ; Santamarina, M; Dos Santos, ES; Teras, L; Toland, AE; Trentham-Dietz, A; Vachon, CM; Volk, AE; Weber-Lassalle, N; Weitzel, JN; Wiesmuller, L; Winham, S; Yadav, S; Yannoukakos, D; Yao, S; Zampiga, V; Zethoven, M; Zhang, ZW; Zima, T; Spurdle, AB; Vega, A; Rossing, M; Del Valle, J; De Nicolo, A; Hahnen, E; Claes, KBM; Ngeow, J; Momozawa, Y; James, PA; Couch, FJ; Macurek, L; Kleibl, Z;
Details: Publication Year 2023-08-15,Volume 29,Issue #16,Page 3037-3050
Journal Title: Clinical Cancer Research
Publication Type: Research article
Abstract: PURPOSE: Germline pathogenic variants in CHEK2 confer moderately elevated breast cancer risk (odds ratio, OR approximately 2.5), qualifying carriers for enhanced breast cancer screening. Besides pathogenic variants, dozens of missense CHEK2 variants of uncertain significance (VUS) have been identified, hampering the clinical utility of germline genetic testing (GGT). EXPERIMENTAL DESIGN: We collected 460 CHEK2 missense VUS identified by the ENIGMA consortium in 15 countries. Their functional characterization was performed using CHEK2-complementation assays quantifying KAP1 phosphorylation and CHK2 autophosphorylation in human RPE1-CHEK2-knockout cells. Concordant results in both functional assays were used to categorize CHEK2 VUS from 12 ENIGMA case-control datasets, including 73,048 female patients with breast cancer and 88,658 ethnicity-matched controls. RESULTS: A total of 430/460 VUS were successfully analyzed, of which 340 (79.1%) were concordant in both functional assays and categorized as functionally impaired (N = 102), functionally intermediate (N = 12), or functionally wild-type (WT)-like (N = 226). We then examined their association with breast cancer risk in the case-control analysis. The OR and 95% CI (confidence intervals) for carriers of functionally impaired, intermediate, and WT-like variants were 2.83 (95% CI, 2.35-3.41), 1.57 (95% CI, 1.41-1.75), and 1.19 (95% CI, 1.08-1.31), respectively. The meta-analysis of population-specific datasets showed similar results. CONCLUSIONS: We determined the functional consequences for the majority of CHEK2 missense VUS found in patients with breast cancer (3,660/4,436; 82.5%). Carriers of functionally impaired missense variants accounted for 0.5% of patients with breast cancer and were associated with a moderate risk similar to that of truncating CHEK2 variants. In contrast, 2.2% of all patients with breast cancer carried functionally wild-type/intermediate missense variants with no clinically relevant breast cancer risk in heterozygous carriers.
Publisher: American Association for Cancer Research
Keywords: Humans; Female; *Breast Neoplasms/epidemiology/genetics; Genetic Predisposition to Disease; Checkpoint Kinase 2/genetics; Mutation, Missense; Germ-Line Mutation; Germ Cells
Department(s): Laboratory Research; Familial Cancer Centre
PubMed ID: 37449874
Publisher's Version: https://doi.org/10.1158/1078-0432.CCR-23-0212
Open Access at Publisher's Site: https://doi.org/10.1158/1078-0432.Ccr-23-0212
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2023-11-14 12:41:57

Last Modified: 2023-11-14 12:43:26